Assessment of stability in extemporaneously prepared venlafaxine solutions

EJHP Practice

Volumn 15, Issue 4, 2009, Pages 30-32

  Schlatter, Joël ^a   Kervela, Jean Gael ^b   Castagnet, Stéphanie ^b   Benabadji, Zahira ^b   Cisternino, Salvatore ^b   Fontan, Jean Eudes ^b  

^a HÔPITAL JEAN VERDIER   (France)

^b NONE

Author keywords

Oral liquids; Stability; Venlafaxine

Indexed keywords

VENLAFAXINE;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DEGRADATION; DRUG FORMULATION; DRUG STABILITY; DRUG STORAGE; GLASS BOTTLE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PH; TABLET; TEMPERATURE;

EID: 70349618765     PISSN: 17819989     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Bradwejn J, Ahokas A, Stein DJ, et al. Venlafaxine extended-release capsules in panic disorder: flexible-dose, double-blind, placebocontrolled study. Br J Psychiatry. 2005;187:352-359.
2. Grossman R, Reynolds D, Goodman M, et al. Efficacy of open-label venlafaxine in subjects with major depressive disorder: Associations with neuroendocrine response to serotonergic and noradrenergic probes. Psychiatry Res. 2004;128(2):203-206.
3. Liebowitz MR, Mangano RM, Bradwejn J, Asnis G; SAD Study Group. A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. J Clin Psychiatry. 2005;66(2): 238-247.
4. Stein MB, Pollack MH, Bystritsky A, et al. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology. 2005;177(3):280-288.
5. Courtney DB. Selective serotonin reuptake inhibitor and venlafaxine use in children and adolescents with major depressive disorder: a systematic review of published randomized controlled trials. Can J Psychiatry. 2004; 49(8):557-563.
6. Wagner KD. Pharmacotherapy for major depression in children and adolescents. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29(5):819-826.
7. Mukaddes NM, Abali O. Venlafaxine in children and adolescents with attention deficit hyperactivity disorder. Psychiatry Clin Neurosci. 2004;58(1):92-95.
8. Makhija SN, Vavia PR. Stability indicating LC method for the estimation of venlafaxine in pharmaceutical formulations. J Pharm Biomed Anal. 2002;28(6):1055-1059.